Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00281593 · ClinicalTrials.gov registry record · Phase 3
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
A Phase 3 study of Hypertension, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,354
- Enrollment target
- 20
- Study locations
NCT00281593: Completed Phase 3 study of Hypertension, sponsored by Boehringer Ingelheim.
NCT00281593 is a Phase 3 study of Hypertension that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,354 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00281593, a Phase 3 study of Hypertension, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,354 participants
- Enrollment target
- 20
- Study locations
Study Summary
To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
Conditions Studied
Interventions
- DRUG Ramipril
- DRUG Telmisartan
Study Locations (20)
California
- 1236.1.523 Boehringer Ingelheim Investigational Site - Buena Park
- 1236.1.514 Boehringer Ingelheim Investigational Site - Concord
- 1236.1.560 Boehringer Ingelheim Investigational Site - Encinitas
- 1236.1.573 Boehringer Ingelheim Investigational Site - Long Beach
- 1236.1.516 Boehringer Ingelheim Investigational Site - Los Angeles
- 1236.1.529 Boehringer Ingelheim Investigational Site - Roseville
- 1236.1.519 Boehringer Ingelheim Investigational Site - Tustin
- 1236.1.543 Boehringer Ingelheim Investigational Site - Westlake Village
Florida
- 1236.1.572 Boehringer Ingelheim Investigational Site - DeLand
- 1236.1.577 Boehringer Ingelheim Investigational Site - Hialeah
- 1236.1.526 Boehringer Ingelheim Investigational Site - Jupiter
- 1236.1.527 Boehringer Ingelheim Investigational Site - Largo
- 1236.1.503 Anchor Research Center - Naples
- 1236.1.520 Boehringer Ingelheim Investigational Site - New Port Richey
Arizona
- 1236.1.511 Boehringer Ingelheim Investigational Site - Glendale
- 1236.1.574 Boehringer Ingelheim Investigational Site - Tempe
- 1236.1.501 Boehringer Ingelheim Investigational Site - Tucson
- 1236.1.557 Boehringer Ingelheim Investigational Site - Tucson
Colorado
- 1236.1.528 Boehringer Ingelheim Investigational Site - Boulder
Connecticut
- 1236.1.530 Boehringer Ingelheim Investigational Site - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,354 participants |
| Start Date | 2006-04 |
| Phase | Phase 3 |
What the finished NCT00281593 record still lists
NCT00281593 is an interventional study that assigns participants to a tested intervention. Its 1,354 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Ramipril is the first listed.
NCT00281593 names 20 study sites across 5 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00281593 about?
NCT00281593 is a clinical study titled "Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension". To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
What is the current status of trial NCT00281593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,354 participants. The study started on 2006-04.
What conditions does trial NCT00281593 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00281593?
The interventions under investigation include: Ramipril (DRUG), Telmisartan (DRUG).
Who is sponsoring clinical trial NCT00281593?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00281593 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00281593's enrollment target sits among peer trials
1,354 48th of 470 higher than 423 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia